Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754702729> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2754702729 abstract "Background Efficacy and safety of Golimumab (Glm) has been demonstrated for spondiloarthritis (SpA). Nonetheless, there is little data determining an association between an optimal drug levels concentration and the maintenance of a good control of disease activity. In Spa-Paz cohort we defined previously an optimal Glm levels concentration associated with a good clinical response. Objectives To investigate the association between serum levels of Glm, based on the optimal concentration defined previously in Spa-Paz cohort, and disease activity in a larger cohort of SpA. Methods Observational prospective SpA-Paz cohort study treated with Glm. Disease activity was measured by ASDAS and clinical improvement using Delta-ASDAS at baseline, 6 and 12 months of biologic therapy. ASDAS 1.4 mg/L. At 12 months we made a LOCF analysis to include patient data (11 patients) with less than 12 months of treatment. We used the software Graph-Pad Prism 6 for statistical analysis. Results 46 patients of 79 with SpA treated with Glm were included in this study. The average age was 49 years old (age range 22–72 years old), 31 men (67%) and 15 women (33%). 22 patients (48%) were non-smokers and 13 (28%) active smokers. 25 (54%) were HLA-B27 positive. In total, 17 patients (37%) were classified in group 1, 16 (35%) in group 2 and 13 (28%) in group 3. At 12 months of therapy, most patients in low disease activity were in groups 2 and 3 but nevertheless, the majority of high disease activity patients were in group 3 (76% in groups 2 and 3 vs. 41% in group 1 with ASDAS 0.0002). There were no differences in clinical improvement between group 2 and 3. 11 patients (24%) discontinued the treatment, 1 for adverse effect and 10 for inefficacy, 50% of which (5 patients) were in group 1 at the suspension moment. Conclusions In our Glm treated SpA cohort, the majority of low activity patients and higher clinical improvement were classified in optimal or supraoptimal concentration group. Overoptimal concentration drug levels do not seem to contribute to major benefit in clinical improvement. Disclosure of Interest None declared" @default.
- W2754702729 created "2017-09-25" @default.
- W2754702729 creator A5012348969 @default.
- W2754702729 creator A5024920644 @default.
- W2754702729 creator A5025235912 @default.
- W2754702729 creator A5035765760 @default.
- W2754702729 creator A5054608926 @default.
- W2754702729 creator A5056993203 @default.
- W2754702729 creator A5058087062 @default.
- W2754702729 creator A5072690427 @default.
- W2754702729 creator A5091008755 @default.
- W2754702729 date "2017-06-01" @default.
- W2754702729 modified "2023-10-01" @default.
- W2754702729 title "AB0686 Association between drug serum levels and disease activity in espondiloarthritis patients treated with golimumab" @default.
- W2754702729 doi "https://doi.org/10.1136/annrheumdis-2017-eular.5881" @default.
- W2754702729 hasPublicationYear "2017" @default.
- W2754702729 type Work @default.
- W2754702729 sameAs 2754702729 @default.
- W2754702729 citedByCount "0" @default.
- W2754702729 crossrefType "proceedings-article" @default.
- W2754702729 hasAuthorship W2754702729A5012348969 @default.
- W2754702729 hasAuthorship W2754702729A5024920644 @default.
- W2754702729 hasAuthorship W2754702729A5025235912 @default.
- W2754702729 hasAuthorship W2754702729A5035765760 @default.
- W2754702729 hasAuthorship W2754702729A5054608926 @default.
- W2754702729 hasAuthorship W2754702729A5056993203 @default.
- W2754702729 hasAuthorship W2754702729A5058087062 @default.
- W2754702729 hasAuthorship W2754702729A5072690427 @default.
- W2754702729 hasAuthorship W2754702729A5091008755 @default.
- W2754702729 hasBestOaLocation W27547027291 @default.
- W2754702729 hasConcept C105795698 @default.
- W2754702729 hasConcept C126322002 @default.
- W2754702729 hasConcept C188816634 @default.
- W2754702729 hasConcept C201903717 @default.
- W2754702729 hasConcept C27403532 @default.
- W2754702729 hasConcept C2779134260 @default.
- W2754702729 hasConcept C2780132546 @default.
- W2754702729 hasConcept C2781290027 @default.
- W2754702729 hasConcept C33923547 @default.
- W2754702729 hasConcept C53084192 @default.
- W2754702729 hasConcept C71924100 @default.
- W2754702729 hasConcept C72563966 @default.
- W2754702729 hasConceptScore W2754702729C105795698 @default.
- W2754702729 hasConceptScore W2754702729C126322002 @default.
- W2754702729 hasConceptScore W2754702729C188816634 @default.
- W2754702729 hasConceptScore W2754702729C201903717 @default.
- W2754702729 hasConceptScore W2754702729C27403532 @default.
- W2754702729 hasConceptScore W2754702729C2779134260 @default.
- W2754702729 hasConceptScore W2754702729C2780132546 @default.
- W2754702729 hasConceptScore W2754702729C2781290027 @default.
- W2754702729 hasConceptScore W2754702729C33923547 @default.
- W2754702729 hasConceptScore W2754702729C53084192 @default.
- W2754702729 hasConceptScore W2754702729C71924100 @default.
- W2754702729 hasConceptScore W2754702729C72563966 @default.
- W2754702729 hasLocation W27547027291 @default.
- W2754702729 hasOpenAccess W2754702729 @default.
- W2754702729 hasPrimaryLocation W27547027291 @default.
- W2754702729 hasRelatedWork W2056013179 @default.
- W2754702729 hasRelatedWork W2068085368 @default.
- W2754702729 hasRelatedWork W2317799447 @default.
- W2754702729 hasRelatedWork W2325698783 @default.
- W2754702729 hasRelatedWork W2335757649 @default.
- W2754702729 hasRelatedWork W2411615486 @default.
- W2754702729 hasRelatedWork W2411669382 @default.
- W2754702729 hasRelatedWork W2412587704 @default.
- W2754702729 hasRelatedWork W2418234358 @default.
- W2754702729 hasRelatedWork W2549198882 @default.
- W2754702729 hasRelatedWork W2550566425 @default.
- W2754702729 hasRelatedWork W2754206965 @default.
- W2754702729 hasRelatedWork W2754251673 @default.
- W2754702729 hasRelatedWork W2888269697 @default.
- W2754702729 hasRelatedWork W2908717813 @default.
- W2754702729 hasRelatedWork W2909234682 @default.
- W2754702729 hasRelatedWork W3164141552 @default.
- W2754702729 hasRelatedWork W3164518662 @default.
- W2754702729 hasRelatedWork W3164792826 @default.
- W2754702729 hasRelatedWork W3209907291 @default.
- W2754702729 isParatext "false" @default.
- W2754702729 isRetracted "false" @default.
- W2754702729 magId "2754702729" @default.
- W2754702729 workType "article" @default.